Stockreport

Revolution Medicines: Pivotal Trial Readouts Coming, And Buyout Rumors Churning [Seeking Alpha]

Revolution Medicines, Inc.  (RVMD) 
PDF Key catalysts include upcoming phase 3 readouts for daraxonrasib in pancreatic cancer (RASolute 302/304), and Breakthrough Therapy designation for zoldonrasib in NSCLC. [Read more]